An Environmental Scan of Canadian Quality Metrics for Patients on In-Center Hemodialysis

Daniel Blum¹, Alison Thomas², Claire Harris³, Jay Hingwala⁴, William Beaubien-Souligny⁵, and Samuel A. Silver⁶

Abstract

Background: Quality metrics or indicators help guide quality improvement work by reporting on measurable aspects of health care upon which improvement efforts can focus. For recipients of in-center hemodialysis (ICH) in Canada, it is unclear what ICHD quality indicators exist and whether they adequately cover different domains of health care quality.

Objectives: To identify and evaluate current Canadian ICHD quality metrics to document a starting point for future collaborations and standardization of quality improvement in Canada.

Design: Environmental scan of quality metrics in ICHD, and subsequent indicator evaluation using a modified Delphi approach.

Setting: Canadian ICHD units.

Participants: Sixteen-member pan-Canadian working group with expertise in ICHD and quality improvement.

Measurements: We classified the existing indicators based on the Institute of Medicine (IOM) and Donabedian frameworks.

Methods: Each metric was rated by a 5-person subcommittee using a modified Delphi approach based on the American College of Physicians/Agency for Healthcare Research and Quality criteria. We shared these consensus ratings with the entire 16-member panel for additional comments.

Results: We identified 27 metrics that are tracked across 8 provinces, with only 9 (33%) tracked by multiple provinces (ie, more than 1 province). We rated 9 metrics (33%) as “necessary” to distinguish high-quality from low-quality care, of which only 2 were tracked by multiple provinces (proportion of patients by primary access and rate of vascular access-related bloodstream infections). Most (16/27, 59%) indicators assessed the IOM domains of safe or effective care, and none of the “necessary” indicators measured the IOM domains of timely, patient-centered, or equitable care.

Limitations: The environmental scan is a nonexhaustive list of quality indicators in Canada. The panel also lacked representation from patients, administrators, and allied health professionals, with more representation from academic sites.

Conclusions: Quality indicators in Canada mainly focus on safe and effective care, with little provincial overlap. These results highlight current gaps in quality of care measurement for ICHD, and this initial work should provide programs with a starting point to combine highly rated indicators with newly developed indicators into a concise balanced scorecard that supports quality improvement initiatives across all aspects of ICHD care.

Trial Registration: not applicable.

Abrégé

Contexte: Les mesures ou indicateurs de la qualité contribuent à guider les travaux d'amélioration de la qualité des soins de santé en indiquant les aspects mesurables sur lesquels les efforts peuvent se concentrer. On connait peu les indicateurs de la qualité existant au Canada pour les bénéficiaires de l'hémodialyse en centre (HDC). On ignore également si ces indicateurs couvrent adéquatement les différents domaines de la qualité des soins de santé.

Objectifs: Définir et évaluer les mesures actuelles de la qualité des soins d'HDC au Canada. Ces travaux serviront à documenter le point de départ de futures collaborations et la normalisation de l'amélioration de la qualité au Canada.

Type d'étude: Analyse contextuelle des mesures de la qualité en HDC, suivie de leur évaluation par une méthode Delphi modifiée.

Cadre: Des unités d'HDC au Canada

Sujets: Un groupe de travail panceanadien constitué de 16 membres ayant une expertise en HDC et en amélioration de la qualité.
Mesures: Les indicateurs existants ont été évalués à l’aide des modèles de l’IOM (Institute of Medicine) et de Donabedian. Méthodologie: Chaque indicateur a été évalué par un sous-comité de cinq personnes à l’aide d’une méthode Delphi modifiée basée sur les critères de l’American College of Physicians/Agency for Healthcare Research and Quality. Les évaluations consentuelles ont été partagées avec l’ensemble des 16 membres pour recueillir des commentaires supplémentaires. Résultats: Nous avons répertorié 27 indicateurs suivis dans 8 provinces, dont 9 (33 %) sont suivis dans plus d’une province. Neuf indicateurs (33 %) ont été classés comme « nécessaires » pour départager les soins de haute qualité des soins de faible qualité, dont seulement deux (la proportion de patients selon l’accès primaire et le taux de bactériémies liées à l’accès vasculaire) sont suivis par plusieurs provinces. La majorité des indicateurs (16/27; 59 %) a évalué les domaines de l’IOM relatifs aux soins sûrs ou efficaces; aucun des indicateurs « nécessaires » n’a mesuré les domaines de l’IOM relatifs aux soins opportuns, centrés sur le patient ou équitables. Limites: Au Canada, l’analyse contextuelle consiste en une liste non exhaustive d’indicateurs de la qualité. Le groupe de travail manquait de représentants des patients, des administrateurs et des professionnels paramédicaux, les sites universitaires étant mieux représentés. Conclusion: Au Canada, les indicateurs de la qualité se concentrent principalement sur la prestation de soins sûrs et efficaces, et les chevauchements entre les provinces sont rares. Ces résultats mettent en évidence les lacunes actuelles dans l’évaluation de la qualité des soins d’HDC. Ces travaux préliminaires devraient fournir aux programmes un point de départ pour combiner des indicateurs bien cotés à d’autres nouvellement développés dans une fiche d’évaluation concise destinée à soutenir les initiatives d’amélioration de la qualité dans tous les aspects des soins entourant l’HDC.

Keywords
hemodialysis, quality indicators, quality improvement

Received July 29, 2020. Accepted for publication September 24, 2020.

Introduction
Each year more than 16 000 Canadians with end-stage kidney disease receive in-center hemodialysis (ICHD), representing three-quarters of all dialysis recipients. People who receive ICHD experience a high use of health care resources, frequent hospitalizations, and poor health-related quality of life. Although much of these poor outcomes and high resource use may be related to comorbid medical conditions, a proportion may be related to system-level factors in the provision of hemodialysis that are amenable to quality improvement efforts.

Quality metrics or indicators help guide quality improvement work by reporting on measurable aspects of health care upon which improvement efforts can focus. Over the last decade, quality metrics have been increasingly used to monitor health system performance through comparative reporting and accountability. In some jurisdictions, certain metrics have been linked with remuneration to incentivize consistent performance. Accordingly, quality metrics should be carefully developed, considering whether they are evidence-based, precisely defined, easily and reliably measured, usable for quality improvement activities, and target important improvements in outcomes. They should also be selected so as to minimize unintended consequences, thereby increasing the value of health care delivery without compromising care. Finally, they should cover different domains and components of health care quality, including the Institute of Medicine (IOM) domains of safe (free from harm), effective (using best available evidence), efficient (limits waste), timely (available when needed), patient-centered (focused on the patient), and equitable (equally available) care, and the Donabedian components of structures (the setting in which care occurs), processes (the care that is done to the patient), and outcomes (how the care ultimately affects the patient).
Despite the increased attention devoted to quality indicators and quality improvement in nephrology, the type and nature of quality metrics currently used in Canadian hemodialysis units has not been documented. Our objectives were to identify, classify, and evaluate ICHD quality metrics that are presently being tracked in Canada, so as to provide a collated resource of existing indicators and inform strategies that may improve future metric development and reporting across Canada.

**Methods**

**Environmental Scan and Indicator Categorization**

We performed an environmental scan to identify metrics that are being tracked across provinces (including British Columbia, Alberta, Saskatchewan, Manitoba, Quebec, Ontario, and the Atlantic Provinces) by reaching out to nephrologists at hemodialysis units located in academic teaching hospitals and select community centers via email and phone. We also collected publicly available indicators from provincial and local nephrology programs. We asked nephrologists what metrics related to ICHD are mandated and/or reported across their province, as well as to describe any local quality improvement projects. We stopped the environmental scan once we achieved representation from all the aforementioned provinces/regions.

We combined similar indicators into a single measure and characterized each indicator according to the IOM and Donabedian frameworks of health care quality. We also included balancing indicators so as to capture measures that look at potential adverse effects of ICHD (eg, infectious complications).

**Indicator Evaluation**

We rated the identified indicators using a modified version of the American College of Physicians/Agency for Healthcare Research and Quality performance measure review criteria, which included the following dimensions (Supplemental Table 1):

- Importance: The metric will lead to measurable and meaningful improvement or there is a clear performance gap;
- Evidence-base: The metric is based on high-quality and high-quantity evidence;
- Measure specifications: The metric can be clearly defined (ie, numerator and denominator) and reliably captured;
- Feasibility and applicability: The metric is under the influence of health care providers and/or the health care system, with data collection and improvement activities both feasible and acceptable.

We rated metrics on a 9-point scale where 1 to 3 indicated “does not meet criteria,” 4 to 6 “meets some criteria,” and 7 to 9 “meets criteria.” Based on these ratings, each indicator received a final global rating based on its overall ability to distinguish good quality from poor quality. We considered indicators as “necessary” if the median global rating was 7, 8, or 9 and there was no disagreement by any member. We considered indicators as “unnecessary” if the median global rating was 1, 2, or 3 and there was no disagreement by any member. We considered all other indicators as “supplemental.”

**Modified Delphi Process**

We used a modified Delphi approach to evaluate the strengths and weaknesses of the metrics identified by the environmental scan using the criteria described above. This process has been used previously to rate performance indicators. In short, the ICHD subcommittee of 5 members (the authorship group) individually reviewed the quality indicators identified in the environmental scan in advance of a teleconference. Through group discussion, panelists arrived at initial group ratings within each of the American College of Physicians/Agency for Healthcare Research and Quality dimensions. We shared these initial group ratings with each ICHD subcommittee member to compare with their individual rating, with feedback provided as needed. Any disagreements prompted further ICHD group discussion until achieving consensus. We then shared these consensus ratings with the entire 16-member volunteer committee (representation from 7 of 10 provinces and most possessing advanced training in quality improvement), with further discussion of any ratings that differed by ≥3 points. The final ratings were approved by the full 16-member committee prior to publication.

**Ethical Considerations**

Formal research ethics board review was not required by Queen’s University based on the Tri-Council Policy Statement for ethical human research, as the focus of the study involved quality indicators and not human participants.

**Results**

Our environmental scan identified 27 ICHD quality of care metrics across 8 provinces in Canada (Table 1). The IOM domains covered included safe (n = 9, 33%), effective (n = 7, 26%), patient-centered (n = 5, 19%), efficient (n = 3, 11%), timely (n = 2, 7%), and equitable (n = 1, 4%). Donabedian categories included outcome (n = 11, 41%), process (n = 8, 30%), balancing (n = 5, 19%), and structure (n = 3, 11%).
Of these 27 indicators, only 9 metrics were tracked in multiple provinces (more than 1 province) and only 4 metrics were tracked in 3 or more provinces (proportion of patients by primary access, proportion of incident patients with goals of care documentation, achievement of anemia targets, and rate of vascular access-related bloodstream infections). None of the metrics measured in multiple provinces assessed efficient or equitable care.

With respect to overall ability to distinguish good quality from poor quality (ie, necessary versus unnecessary for improvement), we rated 9 (33%) indicators as “necessary,” 14 (63%) as “supplemental,” and 4 (15%) as “unnecessary” (Table 2). The 4 “unnecessary” indicators related to laboratory parameters (CKD-MBD targets) or use of medications (ACE/ARB, statins, and erythropoietin-stimulating agents). The 9 “necessary” indicators focused on safe (n = 5, 19%), effective (n = 3, 11%), and efficient (n = 1, 4%) care; none assessed timely, patient-centered, or equitable care. Of the 9 indicators measured by multiple provinces, the panel rated only 2 as “necessary.” These included the proportion of patients by primary access and rate of vascular access-related bloodstream infections.

Among the 21 local hemodialysis programs contacted, most quality improvement initiatives beyond those mandated provincially tracked to the “necessary” metrics of standardized mortality rate (eg, hospitalizations, 30-day rehospitalizations, vaccinations, iatrogenic infections) or dialysis adequacy (eg, target weight achievement, rate of ultrafiltration). None

### Table 1. Environmental Scan of Current Canadian Nephrology Quality Indicators.

| Institute of Medicine Domains of Quality | Donabedian framework of health care quality |
|-----------------------------------------|-------------------------------------------|
|                                            | Structure | Process | Outcome | Balancing |
| Safe                                      | Hand hygiene rate (1)                      | Completion of latent tuberculosis screening within 4 weeks of dialysis initiation (1) | Standardized mortality rate (1) | Rate vascular access-related bloodstream infections per 1000 vascular access days (4) |
|                                          | Proportion of patients by primary access (4) | Rate of patients screened for falls (1) | Incidence of falls (1) | Rate of hospital admissions (1) |
| Effective                                 | Proportion of patients by primary access (4) | Achievement of targets for anemia (3) | Achievement of targets for CKD-MBD (2) | Rate vascular access primary failure rates (1) |
|                                          | Achievement of targets for dialysis adequacy (1) | Proportion of patients on ACE/ARB (1) | Achievement of targets for dialysis adequacy (1) | Erythropoietin-stimulating agent usage and costs (1) |
|                                          | Proportion of patients screened for falls (1) | Proportion of patients on statin (1) | Proportion of patients on ACE/ARB (1) | Proportion of patients screened for falls (1) |
|                                          | Proportion of patients informed about kidney transplant (1) | Number of living donor transplants per year (1) | Proportion of patients by primary access and rate of vascular access-related bloodstream infections |
| Efficient                                 | Proportion of vascular access surgeries completed within target wait times (2) | Proportion receiving kidney transplant within 12 months of dialysis initiation (2) | Proportion receiving kidney transplant within 12 months of dialysis initiation (2) | Vascular access primary failure rates (1) |
| serene                                   | Proportion of patients screened for falls (1) | Patient-reported symptoms on dialysis (2) | Patient-reported symptoms on dialysis (2) | Erythropoietin-stimulating agent usage and costs (1) |
|                                          | Patient-reported satisfaction on dialysis (1) | Proportion receiving kidney transplant within 12 months of dialysis initiation (2) | Dialysis clinic no show rates (1) | Effort failure rates (1) |
| Patient-centered                         | Proportion of patients traveling >1 hour to attend dialysis (1) | Proportion of patients by primary access (4) | Proportion receiving kidney transplant within 12 months of dialysis initiation (2) | Effort failure rates (1) |
|                                          | Proportion of patients by primary access (4) | Proportion receiving kidney transplant within 12 months of dialysis initiation (2) | Proportion receiving kidney transplant within 12 months of dialysis initiation (2) | Effort failure rates (1) |
|                                          | Proportion of patients by primary access (4) | Proportion receiving kidney transplant within 12 months of dialysis initiation (2) | Proportion receiving kidney transplant within 12 months of dialysis initiation (2) | Effort failure rates (1) |
|                                          | Proportion of patients traveling >1 hour to attend dialysis (1) | Proportion of patients screened for falls (1) | Proportion of patients screened for falls (1) | Effort failure rates (1) |
|                                          | Proportion of patients informed about kidney transplant (1) | Proportion of patients informed about kidney transplant (1) | Proportion of patients informed about kidney transplant (1) | Effort failure rates (1) |
| Equitable                                 | Proportion of patients eligible for referral to kidney transplant center (1) | Proportion of patients informed about kidney transplant (1) | Proportion of patients informed about kidney transplant (1) | Effort failure rates (1) |

Note. The denominator is 8 provinces and the table indicates the number of provinces currently using the listed indicator. CKD-MBD = Chronic kidney disease related mineral and bone disorder; ACE = Angiotensin Converting Enzyme; ARB = Angiotensin 2 Receptor Blocker.
| Indicator type | Targets important improvements | Strong level of evidence | Performance gap exists | Precisely defined and specified | Feasible to collect | Usable for QI | Final rating | Additional comment |
|----------------|--------------------------------|--------------------------|------------------------|-------------------------------|-------------------|----------------|--------------|-------------------|
| **Structure**  |                                |                          |                        |                               |                   |                |              |                   |
| Dialysis clinic occupancy | 2                              | 1                        | 3                      |                                |                   |                | 5            | 4                 |
| Proportion of patients traveling $\geq$ 1 hour to attend dialysis | 7                              | 6                        | 5                      |                                |                   |                | 4            | 5                 |
| Achievement of water treatment standards | 8                              | 8                        | 2                      |                                |                   |                | 4            | 7                 |
| **Process**    |                                |                          |                        |                               |                   |                |              |                   |
| Hand hygiene rates | 9                              | 9                        | 7                      | 7                             | 3                 | 7             | 7            |                   |
| Completion of latent tuberculous screening within 4 weeks of dialysis initiation | 5                              | 6                        | 7                      | 4                             | 3                 | 7             | 5            |                   |
| Rate of patients screened for falls | 8                              | 5                        | 7                      | 7                             | 3                 | 4             | 5            |                   |
| Proportion of patients by primary access | 7                              | 7                        | 7                      | 8                             | 8                 | 7             | 7            |                   |
| Proportion of patients informed about kidney transplant | 8                              | 8                        | 6                      | 4                             | 4                 | 7             | 7            |                   |
| Proportion of patients eligible for referral to kidney transplant center | 8                              | 8                        | 7                      | 3                             | 3                 | 8             | 6            |                   |
| Proportion of vascular access surgeries completed within target wait times | 7                              | 4                        | 7                      | 3                             | 3                 | 6             | 5            |                   |
| Proportion of incident patients with documented goals of care conversations within 90 days | 8                              | 4                        | 8                      | 5                             | 4                 | 6             | 6            |                   |
| **Outcome**    |                                |                          |                        |                               |                   |                |              |                   |
| Incidence of falls | 6                              | 7                        | 6                      | 6                             | 6                 | 7             | 7            | Adjustment for case-mix differences is important |
| Standardized mortality rate | 7                              | 8                        | 7                      | 9                             | 9                 | 7             | 7            | Evidence-base remains limited for lower hemoglobin limit |
| Achievement of targets for anemia | 7                              | 8                        | 3                      | 9                             | 9                 | 7             | 6            |                   |
| Achievement of targets for CKD-MBD | 5                              | 3                        | 4                      | 2                             | 9                 | 3             | 3            | Usability may be affected by patient-related factors (eg, extending dialysis time) |
| Achievement of targets for dialysis adequacy | 7                              | 6                        | 4                      | 8                             | 9                 | 7             | 7            |                   |
| Proportion of patients on ACE/ARB | 5                              | 5                        | 5                      | 8                             | 5                 | 7             | 3            | An electronic record that be easily queried would improve feasibility |
| Indicator type                                                                 | Targets important improvements | Strong level of evidence | Performance gap exists | Precisely defined and specified | Feasible to collect | Usable for QI | Final rating | Additional comment                                                                 |
|-------------------------------------------------------------------------------|--------------------------------|--------------------------|------------------------|-------------------------------|---------------------|--------------|-------------|-------------------------------------------------------------------------------------|
| Proportion of patients on statin                                              | 7                              | 7                        | 7                      | 7                             | 4                   | 7            | 3           | Would have to specify a specific subgroup and clear deprescription protocols        |
| Number of living donor transplants per year                                   | 8                              | 8                        | 7                      | 8                             | 8                   | 8            | 9           | May also reflect a missed opportunity for a preemptive transplant                   |
| Proportion of patients receiving kidney transplant within 12 months of dialysis start | 6                              | 7                        | 7                      | 8                             | 8                   | 6            | 6           | Systematic documentation within an electronic record would improve feasibility     |
| Patient-reported symptoms on dialysis                                         | 8                              | 4                        | 7                      | 9                             | 5                   | 5            | 6           | Feasibility issues and low reported response rates are barriers to implementation   |
| Patient-reported satisfaction on dialysis                                      | 8                              | 4                        | 7                      | 8                             | 3                   | 7            | 5           |                                                                                     |
| Balancing                                                                     |                                 |                          |                        |                               |                     |              |             |                                                                                     |
| Incidence of vascular access-related bloodstream infections per 1000 vascular access days | 9                              | 8                        | 7                      | 9                             | 5                   | 8            | 8           | Granular admission data would improve usability (eg, volume-related readmissions)  |
| Incidence of hospital admissions                                              | 9                              | 6                        | 8                      | 7                             | 7                   | 7            | 6           |                                                                                     |
| Vascular access primary failure rates                                         | 7                              | 7                        | 7                      | 7                             | 7                   | 5            | 6           | Documentation within an electronic record would improve feasibility               |
| Erythropoietin-stimulating agent usage and costs                              | 6                              | 3                        | 3                      | 3                             | 5                   | 3            | 3           |                                                                                     |
| Dialysis clinic no show rates                                                 | 6                              | 7                        | 7                      | 8                             | 7                   | 7            | 6           |                                                                                     |

Note. Each domain was rated on a 9-point scale where 1 to 3 indicated "does not meet criteria," 4 to 6 "meets some criteria," and 7 to 9 "meets criteria." After considering and rating each of these domains, the panelists then rated the overall measure (1-3 = unnecessary, 4-6 = supplemental, 7-9 = necessary). CKD-MBD = Chronic kidney disease related mineral and bone disorder; ACE = Angiotensin Converting Enzyme; ARB = Angiotensin 2 Receptor Blocker; QI = quality improvement.
focused on efficient, timely, patient-centered, or equitable care, except for local initiatives to improve health literacy.

Four common themes emerged during the rating process. First, the strength of evidence for most indicators was moderate to strong, with 14 indicators receiving ratings of 7 to 9 and only 3 indicators receiving ratings of 1 to 3. Second, most indicators could be precisely defined and specified, but definitions often varied between provinces. For example, some provinces measure “% of vascular access surgeries completed within target wait times,” where the targets varied between provinces. Third, feasibility of data collection varied across the indicators due to differing provincial infrastructure and electronic medical record (EMR) capabilities; this was particularly problematic for measures that involved medications or were patient-reported. Finally, 8 metrics related to vascular access and transplantation, which may not be completely attributable to ICHD units (eg, % of vascular access surgeries completed within target wait times). The same observations apply to indicators that involve primary care and other specialties, such as falls, goals of care, and hospitalizations.

Discussion

Our environmental scan identified that 27 metrics pertaining to ICHD are currently tracked at the provincial level in Canada. Nine different metrics are being tracked in multiple provinces, but only 2 indicators are tracked in at least 4 provinces. Moreover, we rated only 9 of the 27 metrics as “necessary” to distinguish good quality from poor-quality care based on the American College of Physicians/Agency for Healthcare Research and Quality criteria, with only 2 of these highly rated metrics used by multiple provinces. The 9 highly rated metrics only measured safe and effective care, indicating gaps in the assessment of efficient, timely, patient-centered, and equitable care. This work provides provincial and local hemodialysis programs with a catalog of existing quality metrics from which to choose, as well as highlights domains of quality that require new indicators.

Outside of Canada, quality indicators in nephrology have recently been evaluated by the American Society of Nephrology (ASN) Quality Committee. This group rated 44 ICHD-related indicators, with 33 unique indicators after removing duplicates. Overall, they rated 16 of 33 (48%) highly based on the American College of Physicians/Agency for Healthcare Research and Quality. These findings are consistent with our observation that less than 50% of ICHD metrics are highly rated, as well as the inclusion of highly rated indicators related to vascular access, dialysis adequacy, and transplantation work-up. In both instances, patient-reported outcomes measures were rated as important targets for improvement, but they required changes to increase response rates and usability (ie, tied to frontline staff responses) to maximize their impact on quality of care. Another similarity was the discovery of several nephrology indicators also attributable to other specialties (ie, vascular access complications, hospitalizations, falls, and advance care planning), with the ASN review also rating pneumonia/influenza immunizations and smoking cessation highly. While these mixed attribution indicators should not be completely dismissed, it should be recognized by program administrators that they will require stakeholder engagement outside of nephrology to realize sustained improvement and may be less appropriate pay-for-performance metrics given the influences outside the dialysis unit on target achievement.

In contrast, our ratings differed on several of the ASN review’s highly rated metrics highlighting important considerations in indicator selection and development. While we both rated advance care planning as an important target for quality improvement, our lower overall score reflects current difficulties in measuring whether this process is delivered with sufficient effectiveness to improve patient-centered outcomes. Until such an indicator is developed, we are concerned this promotes measuring a checkbox and gaming rather than improvements in the advance care planning process. We also downgraded indicators without a large performance gap (coined “topped-out measures”), such as dialysis adequacy and achievement of anemia or CKD-MBD targets; moreover, these 3 aforementioned indicators may not be very important to patients, yet dialysis clinicians place a disproportionate amount of focus on them. These metrics could still be followed annually for accountability and patient safety purposes, allowing for the dedication of scarce resources to the frequent assessment of other indicators more in need of quality improvement efforts. Of the ASN review’s highly rated indicators not identified in our environmental scan, several were partly attributable to other specialties (eg, immunizations, smoking cessation), had difficult to measure processes similar to advance care planning (eg, medication accuracy and reconciliation), or required further refinement to avoid unintended consequences (eg, maximum ultrafiltration thresholds).

Our environmental scan across Canada further contributes to quality indicator use and development through the striking imbalance observed across the IOM and Donabedian frameworks. Most indicators are process or outcome measures focusing primarily on safe and effective care. Structure measures are needed to ensure the resources (eg, water quality and staff (eg, staffing ratios) exist to deliver high-quality care. However, many structure measures may be “topped-out” in high-income settings such as Canada, making them more appropriate for quality assurance purposes rather than daily quality improvement activities. Therefore, we suggest the most important gaps are in the underrepresented IOM domains of efficient, timely, patient-centered, and equitable care. Existing indicators in these domains seemed to lack a combination of measurable processes, accepted targets, and practical strategies for quality improvement, which
To initiate these conversations, we have proposed a balanced quality indicator scorecard for ICHD (Table 3). This incorporates all aspects of the IOM and Donabedian frameworks, as well as several of the highly rated indicators—proportion of patients by primary access, rate of vascular access-related bloodstream infections, standardized mortality rate, and proportion of patients informed about kidney transplant. The transplant metric will require some auditing to ensure the delivery of an effective education program rather than checkbox completion, and it may become “topped-out” over time. Where possible, we modified highly rated indicators by the ASN reviews so that they became more attributable to nephrology, such as volume-related hospitalizations instead of all-cause hospitalizations and time from hospital discharge to nephrologist review instead of postdischarge medication reconciliation. Other newly proposed indicators are meant to elicit further discussion of how to routinely measure these in a manner that is useful for quality improvement initiatives. Some metrics may need to be modified or replaced based on existing data infrastructure and EMR capabilities in different provinces to ensure precise and timely measurement is possible. National collaboration may be helpful to overcoming these barriers, and we believe the minimal overlap across provinces presents an opportunity to learn lessons from each other before each province has its own system that limits provincial comparisons and joint quality improvement activities.

Strengths of this work include the structured approach to indicator categorization and evaluation, using the IOM and Donabedian frameworks along with the American College of Physicians/Agency for Healthcare Research and Quality criteria. Our panel also included members from most regions of Canada to represent different practice patterns, many of whom possessed advanced training and real-life expertise in

| Institute of Medicine Domains of Quality | Donabedian framework of health care quality | Balancing |
|----------------------------------------|-------------------------------------------|-----------|
| Safe                                   | Structure                                  | Incidence of vascular access-related bloodstream infections per 1000 vascular access days |
| Effective                               | Process                                    | – Incidence of volume-related hospitalizations |
| Efficient                               | Outcome                                    | – Standardized mortality rate (needs risk adjustment and target specified) |
| Timely                                 | – Proportion of prevalent patients by primary access | – Timely – Time from dialysis initiation to complete multidisciplinary team review |
| Timely                                 | – Proportion of patients informed about kidney transplant (need to ensure it is high-quality information and not simply a checkbox; may get “topped out” in the future if everyone is informed) | |
| Patient-centered                       | – Time from hospital discharge to MD review in the outpatient unit | – Timely – Time from hospital discharge to MD review in the outpatient unit |
| Equitable                               | – Nurse/MD to patient ratios               | – Patient-reported outcome and experience measures |
| Equitable                               | – Proportion of patients with language barriers with staff | |
| Note. Several highly rated indicators from the environmental scan have been populated (in regular font), with indicator gaps (in bold) and additional work needed to complete the scorecard (in italics). |
ICHD and/or quality improvement, ensuring this work is relevant and translatable to frontline improvement efforts.

Although this article is novel in presenting the current state of quality metrics in Canadian hemodialysis units, there are some limitations. First, reported local and provincial quality metrics were solicited by committee members and cannot be considered an exhaustive list. We also only included items specifically identified as quality indicators, and so did not automatically include all items from the Canadian Organ Replacement Register (CORR). Academic viewpoints were overrepresented relative to community-based ICHD practices, which may be important for understanding how to ultimately achieve quality improvement in ICHD at a national level.

Second, we did not focus on the precise operational definitions of the indicators (ie, numerator, denominator, risk adjustment), which will need to be finalized before use. Third, there is some subjectivity to categorization by the IOM and Donabedian domains, as well as the differences between process and outcome measures. This is especially the case for evidence-based processes/surrogates (eg, anemia, dialysis adequacy). Fourth, our committee consisted of physicians and 1 nurse practitioner and did not have representation from allied health, pharmacists, or administrators. The patient perspective was also not represented, which may have overemphasized the views of dialysis providers relative to dialysis recipients. Moving forward, our group intends to involve patients in new indicator development and curation.

Conclusions
By performing a pan-Canadian environmental scan of quality indicators currently in use for ICHD, we identified 27 metrics of which 9 were considered necessary to differentiate between high- and low-quality care. There was little overlap across provinces, with only 9 indicators used by multiple provinces, of which 2 received global ratings ≥7. More than half of the indicators measured safe or effective care, and none of the “necessary” indicators measured the IOM domains of timely, patient-centered, or equitable care. These results should be viewed as the preliminary steps toward development of a balanced scorecard to measure quality of care in ICHD. Future work will require broad stakeholder engagement to combine current indicators and create new indicators that fill the noted gaps, with the ultimate goal of simplifying performance measurement so that it reinforces frontline quality improvement efforts.

Availability of Data and Materials
Data and materials may be made available upon request to the corresponding author.

Acknowledgments
The authors value the support and guidance from Adeera Levin throughout the design and execution of this work. The other 10 volunteer quality committee members include Lisa Dubrofsky, Tamara Glavinovic, Ali Ibrahim, Amber Molnar, Priya Mysore, Krishna Poinen, Sachin Shah, Karthik Tennankore, Amanda Vinson, and Seychelle Yohanna. S.A.S. is supported by a Kidney Research Scientist Core Education and National Training (KRESCENT) Program New Investigator Award (cofunded by the Kidney Foundation of Canada, Canadian Society of Nephrology, and Canadian Institutes of Health Research).

Author Contributions
All co-authors contributed equally to this manuscript.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.A.S. has received speaking fees from Sanofi Canada. The remaining authors have no conflicts of interest relevant to this study. All authors approved the final version of the submitted manuscript. We certify that this manuscript nor one with substantially similar content has been published or is being considered for publication elsewhere.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
Daniel Blum https://orcid.org/0000-0001-5742-0848
William Beaubien-Souligny https://orcid.org/0000-0003-3030-8703
Samuel A. Silver https://orcid.org/0000-0002-1843-6131

Supplemental Material
Supplemental material for this article is available online.

References
1. Canadian Institute for Health Information (CIHI). Annual Statistics on Organ Replacement in Canada: Dialysis, Transplantation and Donation, 2009 to 2018. Ottawa, ON, Canada: Canadian Institute for Health Information; 2019.
2. Canadian Institute for Health Information (CIHI). High Risk and High Cost: Focus on Opportunities to Reduce Hospitalizations of Dialysis Patients in Canada. Ottawa, ON, Canada: Canadian Institute for Health Information; 2016.
3. Molnar AO, Moist L, Klarenbach S, et al. Hospitalizations in dialysis patients in Canada: A National Cohort Study. Can J Kidney Health Dis. 2018;5:1-10.
4. Manns BJ, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Dialysis adequacy and health related quality of life in hemodialysis patients. *ASAIO J*. 2002;48(5):565-569.

5. Lazar EJ, Fleischut P, Regan BK. Quality measurement in healthcare. *Annu Rev Med*. 2013;64:485-496.

6. Schold JD, Bucinelli LD, Phelan MP, et al. Building an ideal quality metric for ESRD health care delivery. *Clin J Am Soc Nephrol*. 2017;12(8):1351-1356.

7. Weiner DE. Assessing quality care in kidney disease: the double-edged sword versus the Gordian knot. *Semin Dial*. 2020;33(1):10-17.

8. Stelfox HT, Straus SE. Measuring quality of care: considering conceptual approaches to quality indicator development and evaluation. *J Clin Epidemiol*. 2013;66(12):1328-1337.

9. Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 2001.

10. Donabedian A. Evaluating the quality of medical care. *Milbank Q*. 2005;83(4):691-729.

11. Weiner D, Watnick S. The ESRD quality incentive program—Can we bridge the Chasm? *J Am Soc Nephrol*. 2017;28:1697-1706.

12. Tummalapalli SL, Peralta CA. Preparing the nephrology workforce for the transformation to value-based kidney care. *Clin J Am Soc Nephrol*. 2019;14(12):1802-1804.

13. Toma M, Dreischulte T, Gray NM, et al. Balancing measures or a balanced accounting of improvement impact: a qualitative analysis of individual and focus group interviews with improvement experts in Scotland. *BMJ Qual Saf*. 2018;27(7):547-556.

14. Agency for Healthcare Research and Quality. AHRQ quality indicators. http://www.qualityindicators.ahrq.gov/. Published 2012. Accessed July 28, 2020.

15. Guttman A, Razzaq A, Lindsay P, Zagorski B, Anderson GM. Development of measures of the quality of emergency department care for children using a structured panel process. *Pediatrics*. 2006;118(1):114-123.

16. Kröger E, Tourigny A, Morin D, et al. Selecting process quality indicators for the integrated care of vulnerable older adults affected by cognitive impairment or dementia. *BMC Health Serv Res*. 2007;7:195.

17. Lindsay P, Schull M, Bronskill S, Anderson G. The development of indicators to measure the quality of clinical care in emergency departments following a modified-delphi approach. *Acad Emerg Med*. 2002;9(11):1131-1139.

18. Greenberg A, Angus H, Sullivan T, Brown AD. Development of a set of strategy-based system-level cancer care performance indicators in Ontario, Canada. *Int J Qual Health Care*. 2005;17(2):107-114.

19. Bell CM, Brener SS, Comrie R, Anderson GM, Bronskill SE. Quality measures for medication continuity in long-term care facilities, using a structured panel process. *Drugs Aging*. 2012;29(4):319-327.

20. Morris AM, Brener S, Dresser L, Daneman N, Dellit TH, Avdic E, Bell CM. Use of a structured panel process to define quality metrics for antimicrobial stewardship programs. *Infect Control Hosp Epidemiol*. 2012;33(5):500-506.

21. Jeffs L, Law MP, Straus S, Cardoso R, Lyons RF, Bell C. Defining quality outcomes for complex-care patients transitioning across the continuum using a structured panel process. *BMJ Qual Saf*. 2013;22(12):1014-1024.

22. Tummalapalli SL, Peralta CA. Preparing the nephrology workforce for the transformation to value-based kidney care. *Clin J Am Soc Nephrol*. 2019;14(12):1802-1804.

23. Krishnan M, Brunelli SM, Maddux FW, et al. Guiding principles and checklist for population-based quality metrics. *Clin J Am Soc Nephrol*. 2014;9:1124-1131.

24. Chassin MR, Loeb JM, Schmaltz SP, Wachter RM. Accountability measures: using measurement to promote quality improvement. *N Engl J Med*. 2010;363:683-688.

25. Tong A, Winkelmaier WC, Wheeler DC, et al. Nephrologists’ perspectives on defining and applying patient-centered outcomes in hemodialysis. *Clin J Am Soc Nephrol*. 2017;12(3):454-466.

26. Solberg LI, Mosser G, McDonald S. The three faces of performance measurement: improvement, accountability, and research. *Jt Comm J Qual Improv*. 1997;23(3):135-147.

27. Flythe JE, Assimon MM, Wenger JB, Wang L. Ultrafiltration rates and the quality incentive program: proposed measure definitions and their potential dialysis facility implications. *Clin J Am Soc Nephrol*. 2016;11(8):1422-1433.

28. Canadian Organ Replacement Register. https://www.cihi.ca/en/canadian-organ-replacement-register-metadata-corr. Published 2020. Accessed July 28, 2020.